Exploratory Next Generation Sequencing to Identify Causative Variants for Therapy-Induced Congestive Heart Failure From Breast Cancer Study E5103 Germline DNA Samples

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with congestive heart failure receiving therapy for breast cancer. Studying samples of germline DNA in the laboratory from patients with congestive heart failure receiving therapy for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to congestive heart failure.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• European American patients with DNA available

• European American patients who developed CHF and patients who did not develop CHF following a full course of treatment with an anthracycline and bevacizumab

• African American cases (based on a drop in left ventricular ejection fraction \[LVEF\] \< 50 or a drop from baseline \> 20 points) and African American controls

Locations
United States
Massachusetts
Eastern Cooperative Oncology Group
RECRUITING
Boston
Time Frame
Start Date: 2014-03-25
Estimated Completion Date: 2100-01-01
Participants
Target number of participants: 162
Treatments
Ancillary-Correlative (whole exome sequencing)
Previously collected germline DNA samples are analyzed via whole exome sequencing.
Related Therapeutic Areas
Sponsors
Leads: National Cancer Institute (NCI)

This content was sourced from clinicaltrials.gov